Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2013 - 2019)

Ultragenyx Pharmaceutical (RARE) has 7 years of Change in Account Payables data on file, last reported at $3.9 million in Q3 2019.

• Change in Account Payables for Q3 2019 came in at $3.9 million, up 298.58% year-over-year; the trailing twelve-month figure through Sep 2019 was $4.2 million (up 517.67% YoY), and the FY2018 annual result was $3.4 million, down 2.52% from the prior year.
• Change in Account Payables advanced to $3.9 million in Q3 2019 per RARE's latest filing, from -$3.5 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.3 million in Q2 2015 and troughed at -$5.3 million in Q3 2015.
• A 5-year average of $400894.7 and a median of $187000.0 in 2016 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 4528.57% in 2015 and fell as far as 825.92% in 2015.
• A 5-year view of Change in Account Payables shows it stood at -$1.4 million in 2015, then climbed by 6.82% to -$1.3 million in 2016, then soared by 68.66% to -$420000.0 in 2017, then soared by 1044.05% to $4.0 million in 2018, then retreated by 1.39% to $3.9 million in 2019.
• Business Quant data shows RARE's Change in Account Payables at $3.9 million in Q3 2019, -$3.5 million in Q2 2019, and -$151000.0 in Q1 2019.